Skip to main content
SpringerLink
Log in

Rheumatologic Conditions

  • Chapter
Dermatological Manifestations of Kidney Disease

  • 1060 Accesses

Abstract

Rheumatologic conditions frequently have cutaneous findings, which, in some cases, may be the initial presenting sign of disease. As health care providers, we need to be keenly aware of clues that are manifested on the skin. Rapid recognition and appropriate management of these dermatologic findings can help to improve patient outcomes. This chapter highlights several of the more common rheumatologic conditions that can affect both the cutaneous and renal systems, including systemic lupus erythematosus, Wegener granulomatosis, polyarteritis nodosa, and other vasculitides. Pathogenesis of the skin findings, along with differential diagnoses, recommendations for workup, and therapeutic options, is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y. PubMed PMID: 9324032.

    CAS  PubMed  Google Scholar 

  2. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology, vol. 1–2. 3rd ed. New York: Elsevier; 2012.

    Google Scholar 

  3. Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006;47(1):13–27. doi:10.1111/j.1440-0960.2006.00217.x. PubMed PMID: 16405478.

    PubMed  Google Scholar 

  4. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P. Lupus erythematosus tumidus—a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol. 2000;136(8):1033–41. PubMed PMID: 10926740.

    CAS  PubMed  Google Scholar 

  5. Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev. 2009;8(6):456–61. doi:10.1016/j.autrev.2008.12.012. PubMed PMID: 19167524.

    CAS  PubMed  Google Scholar 

  6. Weber F, Schmuth M, Fritsch P, Sepp N. Lymphocytic infiltration of the skin is a photosensitive variant of lupus erythematosus: evidence by phototesting. Br J Dermatol. 2001;144(2):292–6. PMID: 11251561.

    CAS  PubMed  Google Scholar 

  7. Arai S, Katsuoka K. Clinical entity of Lupus erythematosus panniculitis/lupus erythematosus profundus. Autoimmun Rev. 2009;8(6):449–52. doi:10.1016/j.autrev.2008.12.011. PubMed PMID: 19162248.

    PubMed  Google Scholar 

  8. Ma L, Bandarchi B, Glusac EJ. Fatal subcutaneous panniculitis-like T-cell lymphoma with interface change and dermal mucin, a dead ringer for lupus erythematosus. J Cutan Pathol. 2005;32(5):360–5. doi:10.1111/j.0303-6987.2005.00331.x. PubMed PMID: 15811122.

    PubMed  Google Scholar 

  9. Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, et al. Chilblain lupus erythematosus—a review of literature. Clin Rheumatol. 2008;27(10):1341. doi:10.1007/s10067-008-0975-0. PubMed PMID: 19125230.

    PubMed  Google Scholar 

  10. Sifuentes Giraldo WA, Ahijon Lana M, Garcia Villanueva MJ, Gonzalez Garcia C, Vazquez DM. Chilblain lupus induced by TNF-alpha antagonists: a case report and literature review. Clin Rheumatol. 2012;31(3):563–8. doi:10.1007/s10067-011-1924-x. PubMed PMID: 22207249.

    PubMed  Google Scholar 

  11. Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol. 1992;128(3):368–71. PMID: 1550369.

    CAS  PubMed  Google Scholar 

  12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7. PMID: 7138600.

    CAS  PubMed  Google Scholar 

  13. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. doi:10.1002/art.34473. PMID: 22553077.

    PubMed Central  PubMed  Google Scholar 

  14. Kallel-Sellami M, Baili-Klila L, Zerzeri Y, Laadhar L, Blouin J, Abdelmoula MS, et al. Pediatric systemic lupus erythematosus with C1q deficiency. Ann N Y Acad Sci. 2007;1108:193–6.

    CAS  PubMed  Google Scholar 

  15. Welch TR, Blystone LW. Renal disease associated with inherited disorders of the complement system. Pediatr Nephrol (Berlin, Germany). 2009;24(8):1439–44. doi:10.1007/s00467-008-1027-3. PMID: 18958500.

    Google Scholar 

  16. Roberts JL, Schwartz MM, Lewis EJ. Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis. Clin Exp Immunol. 1978;31(2):328–38. PMID: 348363.

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Barnhill RL. Textbook of dermatopathology. New York: Health Professions Division, McGraw-Hill; 2004. p. 1093.

    Google Scholar 

  18. Avgerinou G, Papafragkaki DK, Nasiopoulou A, Arapaki A, Katsambas A, Stavropoulos PG. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol. 2012;26(6):762–7. doi:10.1111/j.1468-3083.2011.04161.x. PubMed PMID: 21707772.

    CAS  PubMed  Google Scholar 

  19. Sardy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res. 2009;301(1):93–8. doi:10.1007/s00403-008-0894-6. PubMed PMID: 18797893.

    CAS  PubMed  Google Scholar 

  20. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011;65(6):e179–93. doi:10.1016/j.jaad.2010.06.018. PubMed PMID: 20739095.

    PubMed  Google Scholar 

  21. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88. doi:10.1186/1741-7015-11-88. PubMed PMID: 23557513; PubMed Central PMCID: PMC3616818.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging. 2012;29(3):181–9. doi:10.2165/11598550-000000000-00000. PubMed PMID: 22263748.

    CAS  PubMed  Google Scholar 

  23. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98. PMID: 1739240.

    CAS  PubMed  Google Scholar 

  24. Mubashir E, Ahmed MM, Hayat S, Latif S, Heldmann M, Berney SM. Wegener granulomatosis: a case report and update. South Med J. 2006;99(9):977–88. PubMed PMID: 17004532.

    PubMed  Google Scholar 

  25. Jennette JC. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener’s granulomatosis). Clin Exp Immunol. 2011;164 Suppl 1:7–10. doi:10.1111/j.1365-2249.2011.04357.x. PubMed PMID: 21447122; PubMed Central PMCID: PMC3095856.

    PubMed Central  PubMed  Google Scholar 

  26. Gajic-Veljic M, Nikolic M, Peco-Antic A, Bogdanovic R, Andrejevic S, Bonaci-Nikolic B. Granulomatosis with polyangiitis (Wegener’s granulomatosis) in children: report of three cases with cutaneous manifestations and literature review. Pediatr Dermatol. 2012. doi:10.1111/pde.12034. PMID: 23145989.

    PubMed  Google Scholar 

  27. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013;8:139–60. doi:10.1146/annurev-pathol-011811-132453. PMID: 23347350.

    CAS  PubMed  Google Scholar 

  28. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76–85. PMID: 6336643.

    CAS  PubMed  Google Scholar 

  29. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120(1):12–7. PMID: 8250451.

    CAS  PubMed  Google Scholar 

  30. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512–23. doi:10.1056/NEJM199711203372106. PMID: 9366584.

    CAS  PubMed  Google Scholar 

  31. Cabral DA, Uribe AG, Benseler S, O’Neil KM, Hashkes PJ, Higgins G, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413–24. doi:10.1002/art.24876. PMID: 19877069.

    PubMed  Google Scholar 

  32. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48(3):311–40. doi:10.1067/mjd.2003.212. PMID: 12637912.

    PubMed  Google Scholar 

  33. Stewart C, Cohen D, Bhattacharyya I, Scheitler L, Riley S, Calamia K, et al. Oral manifestations of Wegener’s granulomatosis: a report of three cases and a literature review. J Am Dent Assoc. 2007;138(3):338–48. quiz 96, 98. PubMed PMID: 17332039.

    PubMed  Google Scholar 

  34. Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener’s). Curr Treat Options Cardiovasc Med. 2012;14(2):164–76. doi:10.1007/s11936-012-0165-x. PubMed PMID: 22270373.

    PubMed  Google Scholar 

  35. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80. PubMed PMID: 19451574.

    PubMed  Google Scholar 

  36. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA. 2007;298(6):655–69. doi:10.1001/jama.298.6.655.

    CAS  PubMed  Google Scholar 

  37. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368(9533):404–18. doi:10.1016/S0140-6736(06)69114-9. PMID: 17684188.

    CAS  PubMed  Google Scholar 

  38. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9. doi:10.1002/art.21142. PubMed PMID: 16052573.

    PubMed  Google Scholar 

  39. Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257–66. doi:10.1002/art.27763. PubMed PMID: 20862686.

    PubMed  Google Scholar 

  40. Bosch X. Inflammation: rituximab in ANCA vasculitis and lupus: bittersweet results. Nat Rev Nephrol. 2010;6(3):137–9. doi:10.1038/nrneph.2010.13. PMID: 20186231.

    CAS  PubMed  Google Scholar 

  41. Gomez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev. 2012;11(9):646–52. doi:10.1016/j.autrev.2011.11.007. PMID: 22146313.

    CAS  PubMed  Google Scholar 

  42. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15(3):717–21. PubMed PMID: 14978174.

    CAS  PubMed  Google Scholar 

  43. Laurino S, Chaudhry A, Booth A, Conte G, Jayne D. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant. 2010;25(10):3307–14. doi:10.1093/ndt/gfq187. PubMed PMID: 20368305.

    CAS  PubMed  Google Scholar 

  44. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2(5091):265–70. PubMed PMID: 13560836; PubMed Central PMCID: PMC2026251.

    CAS  PubMed Central  PubMed  Google Scholar 

  45. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener’s granulomatosis. Ann Intern Med. 1967;67(2):393–8. PubMed PMID: 6036397.

    CAS  PubMed  Google Scholar 

  46. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84(5):313–22. PMID: 16148731.

    Google Scholar 

  47. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005;84(2):115–28. PMID: 15758841.

    Google Scholar 

  48. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med. 2002;112(5):386–91. PMID: 11904113.

    PubMed  Google Scholar 

  49. Ramos-Casals M, Jara LJ, Medina F, Rosas J, Calvo-Alen J, Mana J, et al. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med. 2005;257(6):549–57. doi:10.1111/j.1365-2796.2005.01490.x. PMID: 15910559.

    CAS  PubMed  Google Scholar 

  50. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134–42. PubMed PMID: 8578313.

    CAS  PubMed  Google Scholar 

  51. Segelmark M, Selga D. The challenge of managing patients with polyarteritis nodosa. Curr Opin Rheumatol. 2007;19(1):33–8. doi:10.1097/BOR.0b013e328011cb6f. PMID: 17143093.

    PubMed  Google Scholar 

  52. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–41. doi:10.1136/ard.2005.046300. PMID: 16322081.

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323–30. PMID: 16148732.

    Google Scholar 

  54. Yamazaki-Nakashimada MA, Espinosa-Lopez M, Hernandez-Bautista V, Espinosa-Padilla S, Espinosa-Rosales F. Catastrophic Kawasaki disease or juvenile polyarteritis nodosa? Semin Arthritis Rheum. 2006;35(6):349–54. doi:10.1016/j.semarthrit.2006.02.002. PubMed PMID: 16765711.

    CAS  PubMed  Google Scholar 

  55. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69(6):685–8. PMID: 7904442.

    CAS  PubMed Central  PubMed  Google Scholar 

  56. Eleftheriou D, Dillon M, Tullus K, Marks S, Pilkington C, Roebuck D, et al. Systemic polyarteritis nodosa in the young: a single centre experience over 32 years. Arthritis Rheum. 2013. doi:10.1002/art.38024. PubMed PMID: 23754739.

    PubMed  Google Scholar 

  57. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203.

    PubMed  Google Scholar 

  58. Kato T, Fujii K, Ishii E, et al. A case of polyarteritis nodosa with lesions of the superior mesenteric artery illustrating the diagnostic usefulness of three-dimensional computed tomographic angiography. Clin Rheumatol. 2005;24:628.

    PubMed  Google Scholar 

  59. Guillevin L, Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides? Intern Med. 2003;42:313.

    PubMed  Google Scholar 

  60. Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186.

    PubMed  Google Scholar 

  61. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301:235.

    CAS  PubMed  Google Scholar 

  62. Schartz NE, Alaoui S, Vignon-Pennamen MD, et al. Successful treatment in two cases of steroid-dependent cutaneous polyarteritis nodosa with low-dose methotrexate. Dermatology. 2001;203:336.

    CAS  PubMed  Google Scholar 

  63. Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol. 2005;32:1371.

    PubMed  Google Scholar 

  64. Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis. 2004;63 Suppl 2:ii79.

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44:666.

    CAS  PubMed  Google Scholar 

  66. Eftychiou C, Samarkos M, Golfinopoulou S, et al. Henoch-Schonlein purpura associated with methicillin-resistant Staphylococcus aureus infection. Am J Med. 2006;119:85.

    PubMed  Google Scholar 

  67. Yang YH, Huang MT, Lin SC, et al. Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. Clin Exp Immunol. 2000;122:285.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol. 2007;22:2067.

    PubMed  Google Scholar 

  69. Saulsbury F. Clinical update: Henoch-Schonlein purpura. Lancet. 2007;369:976–8.

    PubMed  Google Scholar 

  70. Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Schönlein purpura: a review of 261 patients. Acta Paediatr. 2004;93:1427.

    PubMed  Google Scholar 

  71. Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35:143.

    PubMed  Google Scholar 

  72. Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 1997;40:859.

    CAS  PubMed  Google Scholar 

  73. Pillebout E, Thervet E, Hill G, et al. Henoch-Schonlein purpura associated with malignancy in adults. J Am Acad Dermatol. 2006;55:s65–70.

    Google Scholar 

  74. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999;78:395.

    CAS  Google Scholar 

  75. Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics. 1971;47:1023.

    CAS  PubMed  Google Scholar 

  76. Barnadas MA, Perez E, Gich I, et al. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol. 2004;43:19–26.

    PubMed  Google Scholar 

  77. Iqbal H, Evans A. Dapsone therapy for Henoch-Schonlein purpura: a case series. Arch Dis Child. 2005;90:985–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Schonlein purpura. Cochrane Database Syst Rev. 2009;(3):CD005128.

    Google Scholar 

  79. Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics. 2007;120:1079–87.

    PubMed Central  PubMed  Google Scholar 

  80. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol. 2011;6:509–37.

    CAS  PubMed  Google Scholar 

  81. Gabrielli A, Avvedimento EV, Kreig T. Scleroderma: mechanisms of disease. N Engl J Med. 2009;360:1989–2003.

    CAS  PubMed  Google Scholar 

  82. Sargent JL, Milano A, Bhattacharyya S. TGFb-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130:694–705.

    CAS  PubMed  Google Scholar 

  83. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28(4):281.

    CAS  PubMed  Google Scholar 

  84. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger Jr TA. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104–9. Epub 2010 Aug 2.

    PubMed  Google Scholar 

  85. Wigley FM. Raynaud phenomenon. N Engl J Med. 2002;347:1001–8.

    PubMed  Google Scholar 

  86. Reveille JD, Solomon DH. American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399.

    PubMed  Google Scholar 

  87. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther. 2011;13:R211.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Stege H, Berneburg M, Humke S, Klammer M, et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol. 1997;36(6 Pt 1):938.

    CAS  PubMed  Google Scholar 

  89. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol. 2010;162(2):445–7. Epub 2009 Aug 08.

    CAS  PubMed  Google Scholar 

  90. Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum. 2009;60(12):3821.

    CAS  PubMed Central  PubMed  Google Scholar 

  91. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118(3):461.

    CAS  PubMed  Google Scholar 

  92. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985.

    CAS  PubMed  Google Scholar 

  93. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest. 2001;108(2):241.

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64:ii18–23.

    PubMed Central  PubMed  Google Scholar 

  95. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41.

    CAS  PubMed  Google Scholar 

  96. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  97. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–57.

    CAS  PubMed  Google Scholar 

  98. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64:495–501.

    PubMed  Google Scholar 

  99. Bremmer S, Van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63:1058–69.

    PubMed  Google Scholar 

  100. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010;37:1386–94. Abstract/FREE Full Text.

    PubMed  Google Scholar 

  101. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013;347:f5961.

    PubMed Central  PubMed  Google Scholar 

  102. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6 Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74.

    Google Scholar 

  103. Mallbris L, Larsson P, Bergqvist S, Vingård E, Granath F, Ståhle M. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol. 2005;124:499–504.

    CAS  PubMed  Google Scholar 

  104. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol. 2011;165:1162–8.

    CAS  PubMed  Google Scholar 

  105. Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol. 2010;146:1364–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.

    CAS  PubMed  Google Scholar 

  107. Singh NP, Prakash A, Kubba S, et al. Psoriatic nephropathy—does and entity exist? Ren Fail. 2005;27(1):123–7.

    CAS  PubMed  Google Scholar 

  108. Villaseñor-Park J, Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med. 2012;79(6):413–23.

    PubMed  Google Scholar 

  109. DeRosa G, Mignogna C. The histopathology of psoriasis. Reumatismo. 2007;59 Suppl 1:46–8.

    Google Scholar 

  110. Dervisoglu E, Akturk AS, Yildiz K, et al. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol. 2012;44(2):509–14.

    CAS  PubMed  Google Scholar 

  111. Finlay AY, Kelly SE. Psoriasis—an index of disability. Clin Exp Dermatol. 1987;12:8–112.

    CAS  PubMed  Google Scholar 

  112. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population based study in the United Kingdom. J Invest Dermatol. 2012;132:556–62.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Farmer CK, Stevens PE. Chronic kidney disease: psoriasis—a risk factor for chronic kidney disease? Nat Rev Nephrol. 2014;10(1):12–3.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Pittsburgh, Presbyterian South Tower, Suite 3880, 200 Lothrop Street, Pittsburgh, PA, 15213, USA

    Kseniya Golubets M.D., M.H.S., Dan Ilkovitch M.D., Ph.D. & Lisa M. Grandinetti M.D., F.A.A.D.

Authors
  1. Kseniya Golubets M.D., M.H.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Ilkovitch M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa M. Grandinetti M.D., F.A.A.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa M. Grandinetti M.D., F.A.A.D. .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Nelson Clinic, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA

    Julia R. Nunley

  2. Department of Medicine, Section of Nephrology, University of Illinois at Chicago / Advocate Christ Medical Center, Oak Lawn, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Golubets, K., Ilkovitch, D., Grandinetti, L.M. (2015). Rheumatologic Conditions. In: Nunley, J., Lerma, E. (eds) Dermatological Manifestations of Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2395-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2395-3_5

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2394-6

  • Online ISBN: 978-1-4939-2395-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation